Chronic kidney disease–associated pruritus: a comparison of instruments and associations with patient-reported outcomes using an electronic patient-reported outcome survey in Europe
Correlation between CKD-aP instruments was high overall, but moderate among the subgroup of patients bothered by itch; differences can be partially attributed to the recall period for the KDQOL-36 (4 weeks) vs the AI- and WI-NRS (24 h). The consistent associations of these instruments with poor outcomes underscores the importance to identify and effectively treat HD patients suffering from pruritus.
Authors
- Thilo Schaufler (ORCID: https://orcid.org/0000-0003-1886-829X)
- Murilo Guedes (ORCID: https://orcid.org/0000-0002-3495-852X)
- Hugh C. Rayner (ORCID: https://orcid.org/0000-0002-6392-3940)
- Michel Jadoul (ORCID: https://orcid.org/0000-0001-7369-7812)
- Roberto Pecoits‐Filho (ORCID: https://orcid.org/0000-0002-0255-6710)
- Elham Asgari (ORCID: https://orcid.org/0000-0002-5692-0784)
- Angelo Karaboyas (ORCID: https://orcid.org/0000-0001-8846-5360)
- Nidhi Sukul
- Laura Labriola (ORCID: https://orcid.org/0000-0003-4133-881X)
- Fitsum Guebre‐Egziabher (ORCID: https://orcid.org/0000-0002-1478-6898)
- Despina Ruessmann
- Ronald L. Pisoni
- Charlotte Tu
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Cliniques Universitaires Saint-Luc (BE)
- Inserm (FR)
- University of Michigan (US)
- Hospices Civils de Lyon (FR)
- Vifor Pharma (Switzerland) (CH)
- VA Ann Arbor Healthcare System (US)
- Heartlands Hospital (GB)
- St. Thomas Hospital (CA)
- Hôpital Edouard Herriot (FR)
- Arbor Research Collaborative for Health (US)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2024-09-04
- DOI
- https://doi.org/10.1093/ckj/sfae276
- Citations
- 4
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.14
Funders
- Amgen
- AstraZeneca
- FibroGen
- Akebia Therapeutics